Show Summary Details
Page of

Multidrug-resistant tuberculosis 

Multidrug-resistant tuberculosis
Multidrug-resistant tuberculosis

Caoimhe Nic Fhogartaigh

Page of

PRINTED FROM OXFORD MEDICINE ONLINE ( © Oxford University Press, 2021. All Rights Reserved. Under the terms of the licence agreement, an individual user may print out a PDF of a single chapter of a title in Oxford Medicine Online for personal use (for details see Privacy Policy and Legal Notice).

date: 26 January 2022

Multidrug-resistant tuberculosis (MDR-TB) is increasingly being identified around the world. Treatment options are limited due to the lack of new anti-mycobacterial agents and the side-effect profiles of currently available options. Diagnosis is dependent on both the ability to perform phenotypic susceptibility testing and increasingly on molecular methodologies. A case of MDR-TB is presented and the management discussed. The side effects suffered by the patient and the concomitant resistance to the fluoroquinolones leads the physicians to apply for compassionate use of TMC 207, a new anti-mycobacterial agent.

Access to the complete content on Oxford Medicine Online requires a subscription or purchase. Public users are able to search the site and view the abstracts for each book and chapter without a subscription.

Please subscribe or login to access full text content.

If you have purchased a print title that contains an access token, please see the token for information about how to register your code.

For questions on access or troubleshooting, please check our FAQs, and if you can't find the answer there, please contact us.